Alfredo Alberti

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse
    Martina Gerotto
    VIMM-Venetian Institute of Molecular Medicine, Via Orus 2, Padua, Italy
    J Hepatol 44:83-7. 2006
  2. ncbi What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?
    Alfredo Alberti
    Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Padova, Italy
    Liver Int 29:15-8. 2009
  3. ncbi Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels
    Alfredo Alberti
    Department of Clinical and Experimental Medicine, Venetian Institute of Molecular Medicine, University of Padova, Via Giustiniani, No 2, 35128 Padua, Italy
    J Hepatol 42:266-74. 2005
  4. ncbi HBV therapy: guidelines and open issues
    Alfredo Alberti
    Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Italy
    Dig Liver Dis 43:S57-63. 2011
  5. ncbi Management of hepatitis C
    Alfredo Alberti
    Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani 2, 35100 Padova, Italy
    J Hepatol 38:S104-18. 2003
  6. ncbi Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection
    Alfredo Alberti
    Department of Clinical and Experimental Medicine, Clinica Medica 5, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Ann Intern Med 137:961-4. 2002
  7. ncbi Therapy of acute hepatitis C
    Alfredo Alberti
    Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    Hepatology 36:S195-200. 2002
  8. ncbi Natural history of initially mild chronic hepatitis C
    A Alberti
    Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy
    Dig Liver Dis 36:646-54. 2004
  9. ncbi Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin
    Francesca Dal Pero
    Venetian Institute for Molecular Medicine, Padova, 35129, Italy
    J Infect Dis 196:998-1005. 2007
  10. ncbi A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C
    Moira Marcolongo
    Department of Histology, Microbiology, and Medical Biotechnologies, University of Padova, Padova, Italy
    Hepatology 50:1038-44. 2009

Detail Information

Publications40

  1. ncbi Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse
    Martina Gerotto
    VIMM-Venetian Institute of Molecular Medicine, Via Orus 2, Padua, Italy
    J Hepatol 44:83-7. 2006
    ..CONCLUSIONS: At the end of Peg-IFN plus ribavirin therapy, TMA is superior to PCR in identifying patients with sustained HCV-RNA clearance...
  2. ncbi What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?
    Alfredo Alberti
    Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Padova, Italy
    Liver Int 29:15-8. 2009
    ....
  3. ncbi Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels
    Alfredo Alberti
    Department of Clinical and Experimental Medicine, Venetian Institute of Molecular Medicine, University of Padova, Via Giustiniani, No 2, 35128 Padua, Italy
    J Hepatol 42:266-74. 2005
  4. ncbi HBV therapy: guidelines and open issues
    Alfredo Alberti
    Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Italy
    Dig Liver Dis 43:S57-63. 2011
    ..This review summarises the recent Recommendations produced for the treatment of chronic HBV infection, with particular focus on the 2010 Italian Guidelines...
  5. ncbi Management of hepatitis C
    Alfredo Alberti
    Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani 2, 35100 Padova, Italy
    J Hepatol 38:S104-18. 2003
  6. ncbi Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection
    Alfredo Alberti
    Department of Clinical and Experimental Medicine, Clinica Medica 5, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Ann Intern Med 137:961-4. 2002
    ..The prevalence of significant liver disease in persons with asymptomatic hepatitis C virus (HCV) infection is unclear...
  7. ncbi Therapy of acute hepatitis C
    Alfredo Alberti
    Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    Hepatology 36:S195-200. 2002
    ....
  8. ncbi Natural history of initially mild chronic hepatitis C
    A Alberti
    Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani, 2, 35128 Padua, Italy
    Dig Liver Dis 36:646-54. 2004
    ..On the basis of these findings, patients with initially mild chronic hepatitis C and elevated ALT should be proposed for antiviral therapy in the absence of contraindications...
  9. ncbi Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin
    Francesca Dal Pero
    Venetian Institute for Molecular Medicine, Padova, 35129, Italy
    J Infect Dis 196:998-1005. 2007
    ..Little is known about NS5A sequences of HCV-1a. We investigated whether genetic variability of HCV-1a NS5A correlates with the early HCV kinetics during treatment...
  10. ncbi A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C
    Moira Marcolongo
    Department of Histology, Microbiology, and Medical Biotechnologies, University of Padova, Padova, Italy
    Hepatology 50:1038-44. 2009
    ..Conclusion: Host genetics defined by CRS predict fibrosis progression in males with initially mild chronic hepatitis C and may become a useful parameter for prognostic evaluation and treatment decision...
  11. ncbi Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C
    Silvia Mirandola
    Venetian Institute of Molecular Medicine, Padova, Italy
    Liver Int 29:557-65. 2009
    ..The MTP -493G/T polymorphism may promote liver fat accumulation, but its role in HCV-related steatosis is still unclear...
  12. ncbi Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B
    Giada Sebastiani
    Department of Clinical and Experimental Medicine, University of Padova, Padova 35100, Italy
    World J Gastroenterol 13:525-31. 2007
    ..To assess the performance of several non-invasive markers and of our recently proposed stepwise combination algorithms to diagnose significant fibrosis (F > or = 2 by METAVIR) and cirrhosis (F4 by METAVIR) in chronic hepatitis B (CHB)...
  13. ncbi Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy
    Giada Sebastiani
    Department of Clinical and Experimental Medicine, University of Padova, Italy
    World J Gastroenterol 12:3682-94. 2006
    ..However, their implementation is expected to reduce, but not to completely eliminate, the need for liver biopsy...
  14. ncbi Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis
    Silvia Mirandola
    VIMM Venetian Institute of Molecular Medicine, Padova, Italy
    Gastroenterology 130:1661-9. 2006
    ..We therefore investigated liver MTP gene expression and its lipid transfer activity in untreated cases infected with the major HCV genotypes showing variable degrees of hepatic steatosis...
  15. ncbi PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C
    Martina Gerotto
    Venetian Institute of Molecular Medicine, Padova, Italy
    Antivir Ther 9:763-70. 2004
    ..On the other hand, the PKR gene response to exogenous IFN was similar in responders and non-responders, at least in PBMCs, suggesting that variations in its activation are not major determinants of the outcome of antiviral treatment...
  16. ncbi Heterogeneity of CK2 phosphorylation sites in the NS5A protein of different hepatitis C virus genotypes
    Francesca Dal Pero
    Venetian Institute of Molecular Medicine VIMM, University of Padova, Via Orus, 2, Padova 35129, Italy
    J Hepatol 47:768-76. 2007
    ..The hepatitis C virus NS5A protein is phosphorylated by several cellular kinases, including casein kinase 2 (CK2). Little is known about CK2 phosphorylation of NS5A from different HCV genotypes and clinical isolates...
  17. ncbi Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy
    Gladis Bortoletto
    Venetian Institute of Molecular Medicine, Via Orus 2, 35100 Padova, Italy
    J Clin Virol 50:217-20. 2011
    ..Antiviral therapy for chronic hepatitis C may cause transient on-treatment response followed by post-treatment relapse...
  18. ncbi Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C
    Giada Sebastiani
    Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani, 35100 Padova, Italy
    J Hepatol 44:686-93. 2006
    ..CONCLUSIONS: Stepwise combination of non-invasive markers of liver fibrosis improves the diagnostic performance in chronic hepatitis C. Need for liver biopsy is reduced by 50-70% but cannot be completely avoided...
  19. ncbi SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C
    Giada Sebastiani
    Venetian Institute of Molecular Medicine, Padova, Italy
    Hepatology 49:1821-7. 2009
    ..CONCLUSION: SAFE biopsy is a rational and validated method for staging liver fibrosis in hepatitis C with a marked reduction in the need for liver biopsy. It is an attractive tool for large-scale screening of HCV carriers...
  20. ncbi Impact of a sustained virological response on the long-term outcome of hepatitis C
    Alfredo Alberti
    Department of Histology, Microbiology and Medical Biotechnologies, Venetian Institute of Molecular Medicine, University of Padova, Padova, Italy
    Liver Int 31:18-22. 2011
    ..Outcome modelling suggests that these effects might also include HCV patients treated with milder forms of liver damage...
  21. ncbi Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance?
    Lisa Franceschini
    Venetian Institute of Molecular Medicine VIMM, Padova, Italy
    Hepatology 54:484-94. 2011
    ....
  22. ncbi Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy
    Silvia Mirandola
    Venetian Institute of Molecular Medicine, Padova, Italy Electronic address
    Antiviral Res 96:422-9. 2012
    ..These results suggested that in patients with CHB, HBV-genotype might be relevant in the evolution and development of drug resistance showing also different mutation patterns in the YMDD motif between HBV genotype D and A...
  23. ncbi Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology
    Fiorella Calabrese
    Department of Pathology, University of Padua, Italy
    J Gastroenterol Hepatol 18:1302-8. 2003
    ..The aim of our study was to define TGF-beta system expression in hepatic parenchymal cells and its significance in patients with differing extents of chronic liver disease of viral etiology...
  24. ncbi Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?
    Fabio Farinati
    Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Università di Genova iUnità di Gastroenterologia, Ospedale Belcolle, Viterbo, Italy
    Eur J Gastroenterol Hepatol 21:1212-8. 2009
    ..As sex favorably modulates the natural history of chronic liver diseases and the risk for neoplastic evolution, our study aimed to ascertain whether female hepatocellular carcinoma (HCC) patients are also characterized by better prognosis...
  25. ncbi Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP)
    Silvia Mirandola
    VIMM Venetian Institute of Molecular Medicine, Padova, Italy
    Nutr Metab (Lond) 7:13. 2010
    ....
  26. ncbi Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study
    Alessandro Vitale
    Unità di Chirurgia Epatobiliare e Trapianto Epatico, Azienda Ospedaliera, Universita di Padova, Padova, Italy
    Lancet Oncol 12:654-62. 2011
    ..We aimed to create a prediction model linking the BCLC stage of patients with hepatocellular carcinoma to their 5-year liver transplant benefit...
  27. ncbi Chronic hepatitis B: a critical appraisal of current approaches to therapy
    Robert P Perrillo
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Clin Gastroenterol Hepatol 4:233-48. 2006
    ..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature...
  28. ncbi Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study
    Pierre Pradat
    Department of Hepatology, , Lyon, France
    Hepatology 36:973-7. 2002
    ..In this subset of patients, the indication of liver biopsy and the potential benefit of therapy need to be further evaluated. These results suggest the need to revisit the algorithm for liver biopsy practice...
  29. ncbi Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data
    Calogero Cammà
    IBIM, Consiglio Nazionale delle Ricerche, Palermo, Italy
    Hepatology 39:333-42. 2004
    ..The beneficial effects of peginterferon on liver histology are closely related to virologic response...
  30. ncbi Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C
    Sean D Sullivan
    University of Washington, Seattle, Washington, USA
    Pharmacoeconomics 22:257-65. 2004
    ..The objective of this study was to determine if the gain in SVR with peginterferon alpha-2a plus ribavirin is worth the incremental cost...
  31. ncbi Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?
    Alfredo Alberti
    J Hepatol 40:1032-5. 2004
  32. ncbi Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma
    Maria Stella De Mitri
    Department of Internal Medicine, Cardioangiology, Hepatology, University of Bologna, Bologna, Italy
    J Hepatol 36:116-22. 2002
    ..In 13 HCC cases sequence analysis was also performed in tumor and nontumor liver tissues...
  33. ncbi Non-invasive evaluation of liver fibrosis using transient elastography
    Laurent Castera
    Departments of Hepatology, Hospital Saint André and Haut Lévêque, University Hospital of Bordeaux, Avenue Magellan, Pessac, France
    J Hepatol 48:835-47. 2008
    ..Guidelines are needed for the use of TE in clinical practice...
  34. ncbi Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection: response to Lecube et al
    Giada Sebastiani
    Diabetes Care 28:1838; author reply 1838-9. 2005
  35. ncbi Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C
    Rinaldo Pellicano
    U.O.A.D.U. Gastro-Epatologia, Ospedale S. Giovanni Battista (Molinette, Corso Bramante 88-10126 Torino, Italy
    World J Gastroenterol 11:4484-9. 2005
    ..CONCLUSION: Recombinant human IFN beta-1a, alone or in combination with ribavirin, has an excellent safety profile and, may represent an alternative for chronic hepatitis C patients who are unable to tolerate pegylated alpha-interferon...
  36. ncbi Recent progress and new trends in the treatment of hepatitis B
    Alfredo Alberti
    Department of Internal Medicine, University of Padua, Padua, Italy
    J Med Virol 67:458-62. 2002
    ..10%, P = 0.045), but not in Milan (7 vs. 10%, P = ns)...
  37. ncbi Analysis of immunoglobulin variable kappa gene mutations in cutaneous B-cell lymphoma
    Gladis Bortoletto
    J Dermatol Sci 47:248-52. 2007
  38. ncbi Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B?
    Alfredo Alberti
    Hepatology 38:18-20. 2003
  39. ncbi Implementing non-invasive markers for liver fibrosis in clinical practice
    Giada Sebastiani
    J Hepatol 48:880-1; author reply 881-3. 2008
  40. ncbi Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients
    Alfredo Alberti
    J Hepatol 42:615-24. 2005